ArticleJournal of diabetes science and technology2023
Cost-Utility of an Online Education Platform and Diabetes Personal Health Record: Analysis Over Ten Years.
Article in Journal of diabetes science and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Health economic evaluation of structured education programs for patients with diabetes: a systematic review.Frontiers in public health · 2024Pooled it
- Trial
- Criteria and enabling conditions for assessing cash-releasing interventions: An evidence review in the context of the NHS 'three shifts'.Future healthcare journal · 2026Review
- Observed changes in clinical parameters and healthcare costs among patients enrolled in a diabetes management program in Brazil: a real-world study.BMC endocrine disorders · 2026Article
- Article
- Article
- Influencing factors of psychological insulin resistance among patients with type 2 diabetes: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2025Article
- Article
- Acceptability and implementation of a comprehensive digital diabetes self-management platform (MyWay Diabetes): a qualitative protocol.BMJ open · 2025Article
- Patient Health Record Smart Network Challenges and Trends for a Smarter World.Sensors (Basel, Switzerland) · 2025Review
- Telemedicine Integrated Care Versus In-Person Care Mode for Patients With Short Stature: Comprehensive Comparison of a Retrospective Cohort Study.Journal of medical Internet research · 2024Article
- Could Online Education Replace Face-to-Face Education in Diabetes? A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Diabetes and artificial intelligence beyond the closed loop: a review of the landscape, promise and challenges.Diabetologia · 2024Review
- Usability evaluation of the educational website "understanding my diabetes" for Mexican patients with type 2 diabetes.Frontiers in public health · 2024Article
- Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension.NPJ digital medicine · 2023Review
- Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMy Diabetes My Way (MDMW) is Scotland's interactive website and mobile app for people with diabetes and their caregivers. It contains multimedia resources for diabetes education and offers access to electronic personal health records. This study aims to assess the cost-utility of MDMW compared with routine diabetes care in people with type 2 diabetes who do not use insulin. MATERIALS AND
methodsAnalysis used the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model 2. Clinical parameters of MDMW users (n = 2576) were compared with a matched cohort of individuals receiving routine care alone (n = 11 628). Matching criteria: age, diabetes duration, sex, and socioeconomic status. Impact on life expectancy, quality-adjusted life years (QALYs), and costs of treatment and complications were simulated over ten years, including a 10% sensitivity analysis.
resultsMDMW cohort: 1670 (64.8%) men; average age 64.3 years; duration of diabetes 5.5 years. 906 (35.2%) women: average age 61.6 years; duration 4.7 years. The cumulative mean QALY (95% CI) gain: 0.054 (0.044-0.062) years. Mean difference in cost: -£118.72 (-£150.16 to -£54.16) over ten years. Increasing MDMW costs (10%): -£50.49 (-£82.24-£14.14). Decreasing MDMW costs (10%): -£186.95 (-£218.53 to -£122.51).
conclusionsMDMW is "dominant" over usual care (cost-saving and life improving) in supporting self-management in people with type 2 diabetes not treated with insulin. Wider use may result in significant cost savings through delay or reduction of long-term complications and improved QALYs in Scotland and other countries. MDMW may be among the most cost-effective interventions currently available to support diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.